NCT01764594 - Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Immune System DiseasesAutoimmune DiseasesLupus Erythematosus, SystemicSkin and Connective Tissue DiseasesConnective Tissue Disease

Interventions

BIOLOGICAL

CDP7657

"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"

OTHER

Placebo

Placebo comparator

Trial Locations (21)

102, Brussels

101, Leuven

203, Plovidv

201, Sofia

202, Sofia

301, Berlin

303, Erlangen

305, Frankfurt

306, Greifswald

304, Hanover

302, Kiel

501, Krakow

503, Wroclaw

601, Bucharest

602, Cluj-Napoca

701, Moscow

702, Yaroslavl

401, Hospitalet Del Llobregat

402, Santiago de Compostela

404, Seville

405, Seville